Alkermes and Elan Drug Technologies merge to build promising new CNS-focused company
This article was originally published in Scrip
Executive Summary
Alkermes is to merge with Elan Drug Technologies (EDT), the formulation and manufacturing business unit of Elan, in a cash and stock transaction valued at around $960 million that is expected to be immediately accretive to cash earnings.